Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Arrowhead Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 269
- +1 vs. Q3 2024
- Shares held
- 99.7M
- +1.96M (+2.0%) vs. Q3 2024
- Total value
- $1.88B
- −$21.5M (−1.1%) vs. Q3 2024
- New holders
- 43
- 93 more added
- Sold out
- 42
- 85 more reduced
4 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARWR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 501 | $9.73B |
| Q1 2026 | 437 | $7.58B |
| Q4 2025 | 401 | $7.70B |
| Q3 2025 | 303 | $3.83B |
| Q2 2025 | 281 | $1.67B |
| Q1 2025 | 264 | $1.34B |
| Q4 2024 | 269 | $1.88B |
| Q3 2024 | 272 | $1.90B |
| Q2 2024 | 272 | $2.54B |
| Q1 2024 | 273 | $2.76B |
| Q4 2023 | 266 | $2.37B |
| Q3 2023 | 257 | $2.01B |
| Q2 2023 | 274 | $2.57B |
| Q1 2023 | 257 | $1.85B |
| Q4 2022 | 282 | $2.97B |
| Q3 2022 | 278 | $2.35B |
| Q2 2022 | 279 | $2.54B |
| Q1 2022 | 307 | $3.19B |
| Q4 2021 | 311 | $4.51B |
| Q3 2021 | 297 | $4.16B |
| Q2 2021 | 314 | $5.54B |
| Q1 2021 | 289 | $4.55B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Arrowhead Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Values First Advisors, Inc. | 0 | $0 | 0.00% | −2,685−100.0% | Sold out |
| Clear Point Advisors Inc. | 0 | $0 | 0.00% | −1,853−100.0% | Sold out |
| Picton Mahoney Asset Management | 0 | $0 | 0.00% | −1,031−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −883−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −700−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −305−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −144−100.0% | Sold out |
| Sandy Spring Bank | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −67−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| ClariVest Asset Management LLC | – | – | – | – | Not filed |
| B. Metzler seel. Sohn & Co. Holding AG | – | – | – | – | Not filed |
| Raymond James & Associates | – | – | – | – | Not filed |
| FinTrust Capital Advisors, LLC | – | – | – | – | Not filed |